July 23, 2016 6:14 AM ET


Company Overview of Endocyte, Inc.

Company Overview

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trials to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial in advanced prostate cancer. The company is also developing EC1788, a folate receptor-targeted SMDC that is in preclinical development stage to treat ca...

3000 Kent Avenue

Suite A1-100

West Lafayette, IN 47906

United States

Founded in 1995

78 Employees





Key Executives for Endocyte, Inc.

Chief Executive Officer, President and Director
Age: 50
Total Annual Compensation: $333.6K
Co-Founder, Chief Scientific Officer and Director
Age: 68
Total Annual Compensation: $228.8K
Vice President of Human Resources
Age: 51
Total Annual Compensation: $249.1K
Vice President of Research
Age: 50
Total Annual Compensation: $297.7K
Vice President of Clinical Operations
Age: 59
Total Annual Compensation: $287.0K
Compensation as of Fiscal Year 2015.

Endocyte, Inc. Key Developments

Endocyte, Inc. Appoints Mike Sherman as President and Chief Executive Officer

Endocyte, Inc. announced that Mike Sherman has been appointed president and chief executive officer of the company and added to its board of directors, succeeding Ron Ellis, who has resigned effective immediately. Mr. Sherman has served as Endocyte's chief financial officer since 2006 and undertook the additional role of chief operating officer in 2014. Prior to joining Endocyte in 2006, Mr. Sherman served in various executive roles, most recently as vice president of finance and strategic planning of Guidant Corporation. He also serves on the Board of Directors at Mead Johnson Nutrition.

Endocyte, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016

Endocyte, Inc. reported unaudited earnings results for the first quarter ended March 31, 2016. For the period, the company reported collaboration revenue of $12,000, loss from operations of $10,965,000, net interest income of $152,000, net loss of $10,870,000 or $0.26 per basic and diluted share and comprehensive loss of $10,735,000 against collaboration revenue of $12,000, loss from operations of $10,339,000, net interest income of $189,000, net loss of $10,153,000 or $0.24 per basic and diluted share and comprehensive loss of $10,043,000 a year ago.

Endocyte, Inc., Q1 2016 Earnings Call, May 04, 2016

Endocyte, Inc., Q1 2016 Earnings Call, May 04, 2016

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Endocyte, Inc., please visit www.endocyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.